News & Events
- Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
- Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
- Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)
- Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference
- Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference
- Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out
- Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
- Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660
- Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020
- Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer
- Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates
- Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
- Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
- Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation
- Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights